{"id":910731,"date":"2025-11-17T09:27:01","date_gmt":"2025-11-17T14:27:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/"},"modified":"2025-11-17T09:27:01","modified_gmt":"2025-11-17T14:27:01","slug":"cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/","title":{"rendered":"Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>System of Care to Advance Care for the Most Commonly Inherited Heart Disease<\/em>\n      <\/p>\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Nov.  17, 2025  (GLOBE NEWSWIRE) &#8212; <strong>\u00a0<\/strong>Cytokinetics, Inc. (Nasdaq: CYTK) today announced its support of a three-year initiative led by the American Heart Association to address disparities in access to care, diagnosis, and treatment for people living with hypertrophic cardiomyopathy (HCM), a chronic and often underdiagnosed heart disease that affects hundreds of thousands of individuals across the United States. As a supporter of this multi-stakeholder undertaking, Cytokinetics will contribute its longstanding commitment to the HCM community to help close prevailing gaps between evidence, guidelines, implementation, and equity in healthcare delivery for HCM.<\/p>\n<p align=\"justify\">\u201cToo many patients living with HCM face a lack of awareness about their condition, delayed diagnoses, and limited access to specialty care,\u201d said Robert I. Blum, Cytokinetics\u2019 President and Chief Executive Officer. \u201cWe are proud to support the American Heart Association to advance a more standardized and comprehensive system of care. This important initiative aligns with our science and patient-centric company culture and reinforces our commitment to elevate the standard of care for those living with HCM.\u201d<\/p>\n<p align=\"justify\">An estimated one in 500 people in the U.S. are living with HCM but many remain undiagnosed or untreated until acute symptoms occur. This underdiagnosis has led to inconsistent and fragmented systems of care. The American Heart Association initiative seeks to identify systemic barriers to improve HCM systems of care and improve how patients with HCM are identified, assessed, referred, and treated.<\/p>\n<p align=\"justify\">Cytokinetics\u2019 support will build on a national effort to unify and elevate care for HCM patients by:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">increasing the number of sites participating in a <a href=\"https:\/\/www.heart.org\/en\/professional\/quality-improvement\/hypertrophic-cardiomyopathy-hcm-registry\" rel=\"nofollow\" target=\"_blank\">national HCM Registry<\/a> powered by Get With The Guidelines<sup>\u00ae<\/sup>;<\/li>\n<li style=\"text-align:justify\">broadening certification opportunities for referring centers and personnel to reach more communities and patients;<\/li>\n<li style=\"text-align:justify\">introducing patient support services at key HCM diagnosis and treatment centers; and\u00a0<\/li>\n<li style=\"text-align:justify\">implementing a prospective pilot of the Association\u2019s HCM detection algorithm designed to reduce underdiagnosis.\u00a0<\/li>\n<\/ul>\n<p align=\"justify\">\u201cCytokinetics\u2019 participation underscores the importance of working across sectors to advance heart health,\u201d said Anjali Owens, M.D., co-chair of the American Heart Association\u2019s HCM initiative. \u201cHCM is often inconsistently managed, leading to delayed treatment, increased risk of complications and preventable death. With this added support, we will work to drive meaningful change that empowers patients, informs clinicians, and strengthens the care continuum for HCM.\u201d<\/p>\n<p align=\"justify\">Cytokinetics has been at the forefront of HCM-related research and advocacy activities. In addition to its investigational therapies for HCM and other cardiovascular conditions, the company actively collaborates with patient advocacy organizations, clinicians, and policymakers to enhance disease awareness and improve care pathways.<\/p>\n<p align=\"justify\">To learn more about Cytokinetics\u2019 commitment to the HCM community, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0GGZ9bS2K_YwsdMT61NKjbUhwkBo4jxL-cTeIymG7HbCfJNTUaXTsfkKhPPYzgztYORSAogeU_6Byy1ujXyASE-3g-r_PmjxWstnCxBjWP4=\" rel=\"nofollow\" target=\"_blank\">www.cytokinetics.com<\/a>. To learn more about the initiative, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-yrKQnWSKMAjpjxWnEt7WRBsr2MOUKDH4JJhUWOUf8wr5Z_DM-lq8zSrk4wrMDIgB-pUxbusomMicmnko1-MAj36ar6nvmyx2uVF6bM6pF214GcY-tQgqtuvtLOnOgPK\" rel=\"nofollow\" target=\"_blank\">www.heart.org\/HCMregistry<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Cytokinetics<\/strong>\n      <\/p>\n<p align=\"justify\">Cytokinetics\u00a0is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of <em>aficamten<\/em>, a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). <em>Aficamten<\/em> is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing <em>omecamtiv mecarbil<\/em>, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF),\u00a0<em>ulacamten<\/em>, a cardiac myosin inhibitor with a mechanism of action distinct from <em>aficamten<\/em>, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.<\/p>\n<p align=\"justify\">For additional information about Cytokinetics, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0GGZ9bS2K_YwsdMT61NKjbUhwkBo4jxL-cTeIymG7HZMfESQo0oRFW0EuQx7lQwTWFJtCH07xSSwo0JxW1QLL2K2iHERAuhxIt3z-bG5DvU=\" rel=\"nofollow\" target=\"_blank\">www.cytokinetics.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x-sOzcnxdYb125ar4llVwG3skeYPWj2Ovc3EhihkNL0Q94FUZIyZFhMZneK-kVHqrx2MaJ-vz31hGbsOlGrnahmwo-EIEE0O0ktG1yatrthXMoncADph9b0Q0qDFsk65MPUAUrp6W7cyxvs36em8YXm0-yVoMhP14uzK2A1Hkb8z6OJBWMNiQcjLoneyJcCjj9E9zE8p6qXNlY_gJdbXJT0Sp0bENV747P-GW5ioTBnexFa6-5pmPjemuSJ7y02-N4UAEQSCAp_6a_jy_s6w9vAvDFpbEEua6NU3xvcZ-s9FhxedJUtxe-qkJ6rv4APa12M_vLHT_vPRNwptZR9-L016X0nFwYMvacurQM85oVsoLbwPWOiZOfLKxZbWeYuL3gTycBHWS-7QrvknJLYYY6gVYH-mx7NlYfSJYik1ISJaIFQ0UoHtdpUeN8fYBtpRZGyl5m33adsqvCsR0j_y9wyETTGIEV1bvmkU1tC1-9lEv-JVNw4sNZ8MmuRs2B-jrBBtF0ycZiwMQWZotlb4amChcRMCIZXQ3Bn3HmPAjHmMbKkbX0oUwZEXDXAayP-ANPVXGvb0X9fS92UVJGzgfdGLgoJx_Em283c8eR8RPcM=\" rel=\"nofollow\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_XoyhFPZtzmq_vK4Lx1UJT0TzHJwMsBiKq7SnRs6VVW02Y_39VBxbTzimAoztRwGjJiO1LcrYLiJ708oUua_EldRtihlatjbVxGFoqRhtq3bogRzay_A5Negv4_HkPdGvVFT-PYeZFokMDAkwPo8gtjkedGrmQ4jsQ0Yh-GansH7XjqTqLCpaDBXk_wudQiG0Y1a3vi3MB_DwrJghuz6p97koayOvY0aiV-_vUp-Jm0MWoiyYd9IzPx2s0HtbipJ-bcP2GSTYxZWBL2F6keXEsiB71Mf_47ZH_roxIx4qG5ptXZUjp8YHeqVGAgUp58yiXGu1-c61T_dBKAcilP-PGBHPeVW-5tSQeji6G2voSEKBxPVOSM8biVELw9MVTYYZad-t7pncP_VFaAbuDKKS580Xw8iLeDcFrZvV5xGl44xn-Tsr_4RlW79B0nZjtm7muDo3PKJHPxxwx2SSFnQYcSQOdHnYubo_4VkMud8TdtbDCZ5jpZbqnosDgAn7Cb6Og7K9YWSjg2G_s2lVz1OTPgKTSoTrvFIdNgnmOKm4VQCk59mXuv_YgURHN8oxE8l6inhiL-FxOIOXQrrcK6KtEEGa5Y0E8qW2br7hxJoFsjfjbsdWeIq5G7vErcbHfaJIkBRQ-VRZG-t6D9bM_oT6Js69glfCTsFy30_sHmXAVERICXH0XL2KzwKNXOEqYuLbtHw67ir-REg2txGwyaS---KRCkmcpQiVaUBcI9YQlPgCMDH1Qvl7hgwEp0rdyiC\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VwxZbn56M2Pnbf8QwXksV6PfgwLKHp_8mQBKPqx2XAeR4cda8fA62BIu3TNT-h2OOQdZbnn4ULhj2P1kPxtCPTpNfcD7Y4SbEDUKL802Xbf4K29qOqY4HfTkOftMy_mpiY5f50imPmS3i06B50_oyIovcJVsX-GRjpRZiFxY7SI5jrEhlzhmXcmIux7T52SGyTlCM3S5I9srIUPOC0C-sB_HWweXdjBal48Q-uJ9Xbi68YPp-YW9esP8DSrOMWjkbPkPDm_OVDuSofEDOlmyTxVzIkZSYCQc4yfonu57NpimPfvc1n3EFIKWnRtUSAKiuSozSF4Gis2df-amuqPYqKWT7bv7owmbmMdn1SJllUYVzEtcLkUtgn6BlmdQ0-lmuoJUghiEwoiwFKQJxXIQAF8bECLqCmweE_KKTgBsU15HaLYsHGDOVq6ucW334XGvi7nSdmZi-t9zkRT73LT77pA85MdoigWOX44tqbIJ_fwmkgJM4HFIWt81t90lGi7giql6VCSI_QeywgWny6FIFEqr34bBchc2Rd1uedmXFGQi_skiIy6blYPrl3vQR82w1FCx7H8kDTROybea3Mvk9QYuf_AxnIvXL9e5AJdb2kZbI0RcJr_POaX7yabuxlNnRvUIqbzdA35rb4s22cDqPjU5GgyKvLgoMOl3MW6gjsS1zQteCO0jaT33hotTblKd\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ipz0xUVm9MhMo8gBq5wtuTbtofCMK2o-upJtC4LAU5ryFnTIl7QC3NU8zz5FL_TAr6zFN3doE_J4z6UzE4GWfWFuz5tQS6240saPUOvq7xRQZrVStGiCk9Kdj0X1N9zzo4jcfRikU1KgE20zzWP-mkwGTBFcP1BBw9XYw_Hp12x7Pmb3YVakvGULAQBStMZD0UuG_jnlQMYKbD-0JwlL1BFTDyM5Fwz1TxOZiHl5AMLWgZYgMUh4iRpDhLCcipgx5xg6hq3ZDqQyuhPsDFflFWcG6U-tNK6O77MoL466794XM4355vVFEHEt8E-iJPrKXsKNVC-zF-iI1zopCkEtxebG3L8a7C4VahEnJig5R1YBgDAIYW0vu4isWjPOhWkL1APTlZNz4fxQkJXXls74E4-D6N_ruhQdm0Y-0X9Yy_BKPWTHngZfRIx4Z0RNPf3zDwO4MoTNN8sHxsyVGpPrnwxBB6XQyFxs0H_5266t4SNf6OyGRUvNkggiuEFXOmRwZDkEe4X8sTOtwqh6uUpSGMK1ZZNIxARSdiAmf1milVVq7ZMH_V3LDfUDOykg3IGmKXF6aFGeghVqOWJfjMi322RVwsPgjRqgecdOJ7QxI4HRTAR_MOCHEjwy3GGa8V8iRFWRamRBcdjmcqXkQr4KJe4O83IvLKNmkhxN-a0M8LOVI4QpU3KWu2y6lLQIkxYu2lybslIRcph71HcXIHK5PQYXsPZqlZJPUkApBXD2sT4fKLD8jWAuWEQ4aPUhfL1c\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Disclaimer<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>Aficamten, omecamtiv mecarbil, ulacamten <\/em>and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \u201cAct\u201d). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act\u2019s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics\u2019 and its partners\u2019 research and development activities of Cytokinetics\u2019 product candidates. Such statements are based on management\u2019s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics\u2019 business outlines in Cytokinetics\u2019 filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics\u2019 actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Cytokinetics<br \/>Diane Weiser<br \/>Senior Vice President, Corporate Affairs<br \/>(415) 290-7757<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Njk5NyM3MjY3MTUwIzIwMDUxMDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDIwNjg1NGEtNjVmNC00MDBlLTg0OWUtOTRmMzVjNmY1MjM5LTEwMTY2NzYtMjAyNS0xMS0xNy1lbg==\/tiny\/Cytokinetics-Incorporated.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>System of Care to Advance Care for the Most Commonly Inherited Heart Disease SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Cytokinetics, Inc. (Nasdaq: CYTK) today announced its support of a three-year initiative led by the American Heart Association to address disparities in access to care, diagnosis, and treatment for people living with hypertrophic cardiomyopathy (HCM), a chronic and often underdiagnosed heart disease that affects hundreds of thousands of individuals across the United States. As a supporter of this multi-stakeholder undertaking, Cytokinetics will contribute its longstanding commitment to the HCM community to help close prevailing gaps between evidence, guidelines, implementation, and equity in healthcare delivery for HCM. \u201cToo many patients living with HCM face a lack of awareness &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-910731","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"System of Care to Advance Care for the Most Commonly Inherited Heart Disease SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Cytokinetics, Inc. (Nasdaq: CYTK) today announced its support of a three-year initiative led by the American Heart Association to address disparities in access to care, diagnosis, and treatment for people living with hypertrophic cardiomyopathy (HCM), a chronic and often underdiagnosed heart disease that affects hundreds of thousands of individuals across the United States. As a supporter of this multi-stakeholder undertaking, Cytokinetics will contribute its longstanding commitment to the HCM community to help close prevailing gaps between evidence, guidelines, implementation, and equity in healthcare delivery for HCM. \u201cToo many patients living with HCM face a lack of awareness &hellip; Continue reading &quot;Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-17T14:27:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Njk5NyM3MjY3MTUwIzIwMDUxMDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy\",\"datePublished\":\"2025-11-17T14:27:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\\\/\"},\"wordCount\":890,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Njk5NyM3MjY3MTUwIzIwMDUxMDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\\\/\",\"name\":\"Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Njk5NyM3MjY3MTUwIzIwMDUxMDM=\",\"datePublished\":\"2025-11-17T14:27:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Njk5NyM3MjY3MTUwIzIwMDUxMDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3Njk5NyM3MjY3MTUwIzIwMDUxMDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/","og_locale":"en_US","og_type":"article","og_title":"Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy - Market Newsdesk","og_description":"System of Care to Advance Care for the Most Commonly Inherited Heart Disease SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Cytokinetics, Inc. (Nasdaq: CYTK) today announced its support of a three-year initiative led by the American Heart Association to address disparities in access to care, diagnosis, and treatment for people living with hypertrophic cardiomyopathy (HCM), a chronic and often underdiagnosed heart disease that affects hundreds of thousands of individuals across the United States. As a supporter of this multi-stakeholder undertaking, Cytokinetics will contribute its longstanding commitment to the HCM community to help close prevailing gaps between evidence, guidelines, implementation, and equity in healthcare delivery for HCM. \u201cToo many patients living with HCM face a lack of awareness &hellip; Continue reading \"Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-17T14:27:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Njk5NyM3MjY3MTUwIzIwMDUxMDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy","datePublished":"2025-11-17T14:27:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/"},"wordCount":890,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Njk5NyM3MjY3MTUwIzIwMDUxMDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/","name":"Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Njk5NyM3MjY3MTUwIzIwMDUxMDM=","datePublished":"2025-11-17T14:27:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Njk5NyM3MjY3MTUwIzIwMDUxMDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3Njk5NyM3MjY3MTUwIzIwMDUxMDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-supports-american-heart-association-initiative-to-improve-care-for-people-living-with-hypertrophic-cardiomyopathy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=910731"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910731\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=910731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=910731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=910731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}